49th Annual Meeting and Tox Expo
Salt Lake City, Utah, USA
March 7-11, 2010

"Preclinical Anticancer Drug Development: Shifting Challenges"

9:45     Welcome, Introductions and 
             Market Overview
−          Michael Prosser
          Head of Business Development
          Accelera Srl

9:50     Anticancer Candidate Selection

−           Pietro Grossi

           Senior Director DMPK/ART

           Accelera Srl

10:05   IND Packages and 
             Risk Assessment

−           Paolo Colombo
           Director of ADMET

           Accelera Srl

10:20   Regulatory Perspective: 
             The Impact of ICH S9

−           Marco Brughera

           Vice President
           Accelera Srl

10:30    Combination Treatments:
              Preclinical Challenges

−           Klaus Krauser
           VP,Global Head Toxicology
           Merck Serono R&D

10:40    Q&A

−            All

REFRESHMENTS WILL BE SERVED

If you would like to schedule a meeting with an Accelera representative at the SOT, or if you need more information on services we provide, please visit our website at www.accelera.org or contact us at info@accelera.org 

For further information regarding SOT:
http://www.toxicology.org/ai/meet/am2010/